Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NAGEthis companyNiagen Bioscience Inc	$2.21	28.91×	6.58×	3.89×	22.48×	-158.9%	64.3%	11.0%	13.4%	22.7%	15.6%	2.6%	0.04×	-3.16×	0×	4.86×	0.0%	4	5.33	4	A-
AKBAAkebia Therapeutics, Inc.	$0.51	-77.4×	12.7×	1.75×	20.5×	-604.2%	83.3%	9.9%	-2.3%	-16.4%	9.3%	16.4%	6.63×	1.45×	0.97×	1.13×	0.0%	3	-5.78	1	D+
CRVSCorvus Pharmaceuticals, Inc.	$11.10	-40.53×	9.93×	0×	-39.82×	-99.8%	0.0%	0.0%	0.0%	-25.0%	-69.1%	-5.4%	0.02×	0.24×	0×	6.21×	0.0%	2	32.84	2	C
KROSKeros Therapeutics, Inc.	$9.64	8.7×	2.5×	3.11×	5.22×	-547.0%	99.4%	28.9%	35.7%	28.7%	20.9%	14.0%	0.06×	-2.9×	0×	15.45×	0.0%	3	2.59	3	B
OLMAOlema Pharmaceuticals, Inc.	$7.24	-13.37×	4.55×	0×	-13.14×	-93.1%	0.0%	0.0%	0.0%	-33.9%	-37.0%	-6.7%	0×	0.29×	0×	9.95×	0.0%	2	4.21	2	C+
RGNXREGENXBIO Inc.	$8.09	-3.83×	7.23×	4.36×	-7.27×	-438.7%	88.1%	-94.6%	-113.8%	-188.7%	-42.1%	-17.0%	2.54×	-1.7×	-3.58×	2.38×	0.0%	2	-3.81	1	D+
Peer median	—	-13.37×	7.23×	1.75×	-7.27×	-438.7%	83.3%	0.0%	0.0%	-25.0%	-37.0%	-5.4%	0.06×	0.24×	0×	6.21×	0.0%	2	2.59	2	—